GeneFerm Biotechnology Co Ltd (1796) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of GeneFerm Biotechnology Co Ltd stock TWD 29.32, price TWD 26.65, upside +10.0%, quality 73 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 26.10 TWD – 149.87 TWD · fair‑value band 27.99 TWD – 37.29 TWD · the 26.65 TWD price screens below the 29.32 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow GeneFerm Biotechnology Co in your weekly email
Every Wednesday you see whether GeneFerm Biotechnology Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health products in Taiwan and internationally.
Show moreShow less
The company provides microbial fermentation products, including fungi, bacteria, lactic acid bacteria, yeast, algae, etc.; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reishi mycelia, phellinus linteus mycelia powder, armillaria mellea mycelia powder, beta-glucan powder, and fruits and vegetables fermented enzyme, as well as probiotics and peptide ingredients.
It also provides private label supplements; and microbial fermentation toll manufacturing services. The company was founded in 1999 and is headquartered in Tainan City, Taiwan.
Stock analysis
GeneFerm Biotechnology Co Ltd (1796) currently trades at 26.65 TWD, while our model-based Fair Value estimate is 29.32 TWD, so the stock looks roughly fairly valued today (gap 9.1%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 41.36 TWD per share, and 13 of the 26 models we run sit above the 26.65 TWD price.
Bear case: the Asset-Based group reads lowest at 3.17 TWD, and 13 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 27.99 TWD (bear) to 37.29 TWD (bull), the price of 26.65 TWD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 73/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
GeneFerm Biotechnology Co Ltd reported revenue of 677M TWD in FY2025 versus 522M TWD in FY2021, a compound +6.7%/yr. Reported net income was 28.9M TWD in FY2025, compounding −15.8%/yr from FY2021.
Key figures
Market cap 1.1B TWD (≈ $33.7M) Micro · P/E ratio 63.5 · P/S ratio 1.66 · EPS (TTM) 0.4200 TWD · Dividend yield 2.6% · Net margin 2.6% · Return on equity 2.2% · Return on assets (EBIT) 5.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 10%, 1796 screens cheaper than that median.
Fair Value models
Bear27.99 TWDFair Value 29.32 TWDBull37.29 TWD
Price 26.65 TWD · Upside +10.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.88/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+29.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.0%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.6%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+2.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.2%
Dividend (yield on the price)2.6%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 7%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+3.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +2.2% a year for the price.
Compare GeneFerm Biotechnology Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score73 · Top 25%
Fair Value upside+10.0% · Above median
Profitability
Return on equity (12 months)2.2% · Below median
Return on assets2.3% · Below median
Net margin (12 months)2.6% · Below median
Operating margin (12 months)1.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)0.6% · Below median
Dividend yield (12 months)2.6% · Above median
Balance sheet
Debt / equity0.25× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)63.5× · Priciest 25%
P/B1.35× · Cheaper than median
P/S (12 months)1.66× · Cheaper than median
Price / free cash flow (fiscal year)14.6× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "GeneFerm Biotechnology Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1796
Frequently asked questions
Is GeneFerm Biotechnology Co Ltd (1796) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 29.32 TWD versus a price of 26.65 TWD, about +10% upside (fairly valued).
What is the fair value of 1796?
Our model-based fair value for GeneFerm Biotechnology Co Ltd is 29.32 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 26.65 TWD.
What is the quality score of 1796?
GeneFerm Biotechnology Co Ltd has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GeneFerm Biotechnology Co Ltd (1796)?
Our model-based price target is the fair value of 29.32 TWD (as of Nov 9, 2026) from 26 valuation models. Cautious scenario 27.99 TWD, optimistic scenario 37.29 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the GeneFerm Biotechnology Co Ltd stock forecast for 2026?
Our models put fair value at 29.32 TWD, about +10% upside versus a price of 26.65 TWD (fairly valued). Cautious scenario 27.99 TWD, optimistic scenario 37.29 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of GeneFerm Biotechnology Co Ltd (1796)?
GeneFerm Biotechnology Co Ltd reported trailing-twelve-month revenue of about 665M TWD (latest available figure, as of Nov 9, 2026).
Does GeneFerm Biotechnology Co Ltd pay a dividend?
GeneFerm Biotechnology Co Ltd currently shows a dividend yield of 2.63% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of GeneFerm Biotechnology Co Ltd (1796) and when is the ex-dividend date?
GeneFerm Biotechnology Co Ltd pays a dividend of 0.7 TWD per share a year, a dividend yield of 2.6%. The last ex-dividend date was Jul 14, 2026. The payout ratio is 167% of earnings. Free cash flow covers the dividend 2.61 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into GeneFerm Biotechnology Co Ltd (1796)?
For today's price to be fair in a discounted-cash-flow model, GeneFerm Biotechnology Co Ltd would have to grow free cash flow by +3.8 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.0 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 1796 use?
Our models discount GeneFerm Biotechnology Co Ltd at 9.0 %: a base by market capitalisation (nano), damped by beta 0.08, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For GeneFerm Biotechnology Co Ltd that is +3.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has GeneFerm Biotechnology Co Ltd (1796) delivered so far?
Over the past 5 years revenue at GeneFerm Biotechnology Co Ltd grew +13.0 % a year. The price currently implies free-cash-flow growth of +3.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of GeneFerm Biotechnology Co Ltd (1796) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into GeneFerm Biotechnology Co Ltd (+3.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of GeneFerm Biotechnology Co Ltd (1796)?
The free-cash-flow yield on the price is 6.87 %: that much free cash flow GeneFerm Biotechnology Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of GeneFerm Biotechnology Co Ltd (1796)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GeneFerm Biotechnology Co Ltd it is 29.32 TWD per share (as of Nov 9, 2026), against a price of 26.65 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is GeneFerm Biotechnology Co Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 1796 trades below its calculated fair value: price 26.65 TWD, fair value 29.32 TWD, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1796?
No. The price is what the market pays today (26.65 TWD); the fair value is what the company's own numbers justify (29.32 TWD). For GeneFerm Biotechnology Co Ltd the two are 2.67 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is GeneFerm Biotechnology Co Ltd worth?
The market values GeneFerm Biotechnology Co Ltd at about 1.1B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 26.65 TWD; our models calculate a fair value of 29.32 TWD per share.
What do the bullish and bearish scenarios say about 1796?
Our models span a range for GeneFerm Biotechnology Co Ltd: cautious scenario 27.99 TWD, base 29.32 TWD, optimistic 37.29 TWD per share (as of Nov 9, 2026, price 26.65 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1796?
GeneFerm Biotechnology Co Ltd trades at a price-to-earnings ratio of 63.5 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 29.32 TWD is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2017 to 2025), reported earnings: 48.4. Other multiples: P/B 1.4, P/S 1.7, EV/EBITDA 12.0.
How solid is the balance sheet of GeneFerm Biotechnology Co Ltd (1796)?
Balance-sheet figures for GeneFerm Biotechnology Co Ltd (as of Nov 9, 2026): return on equity 2.2%, debt of 0.25 per unit of equity. They feed the Quality Score of 73/100, which measures business quality independently of the share price.
How far is 1796 from its 52-week high?
GeneFerm Biotechnology Co Ltd trades at 26.65 TWD, about 47% below its 52-week high of 50.60 TWD and 2% above the low of 26.10 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 29.32 TWD is for.
Which stocks are comparable to GeneFerm Biotechnology Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GeneFerm Biotechnology Co Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 26.65 TWD, calculated fair value 29.32 TWD (+10%), Quality Score 73/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1796 calculated?
We run GeneFerm Biotechnology Co Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 29.32 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. GeneFerm Biotechnology Co Ltd currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GeneFerm Biotechnology Co Ltd (1796)?
The closing price on Nov 6, 2026 was 26.65 TWD. Our model-based fair value is 29.32 TWD, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GeneFerm Biotechnology Co Ltd right now?
The price is below even our cautious bear case (27.99 TWD). The market is more pessimistic than our downside scenario. The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of GeneFerm Biotechnology Co Ltd
How large is the market capitalisation of GeneFerm Biotechnology Co Ltd (1796)?
The market capitalisation of GeneFerm Biotechnology Co Ltd is 1.1B TWD (≈ $33.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of GeneFerm Biotechnology Co Ltd (1796)?
The price-to-sales ratio of GeneFerm Biotechnology Co Ltd is 1.66 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of GeneFerm Biotechnology Co Ltd (1796)?
Earnings per share at GeneFerm Biotechnology Co Ltd are 0.4200 TWD (price ÷ EPS = P/E 63.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of GeneFerm Biotechnology Co Ltd (1796)?
The dividend yield of GeneFerm Biotechnology Co Ltd is 2.6% (payout 167%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of GeneFerm Biotechnology Co Ltd (1796)?
The net margin of GeneFerm Biotechnology Co Ltd is 2.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of GeneFerm Biotechnology Co Ltd (1796)?
The return on equity (ROE) of GeneFerm Biotechnology Co Ltd is 2.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GeneFerm Biotechnology Co Ltd (1796)?
On an EBIT basis the return on assets of GeneFerm Biotechnology Co Ltd is 5.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of GeneFerm Biotechnology Co Ltd (1796)?
The operating margin of GeneFerm Biotechnology Co Ltd is 1.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at GeneFerm Biotechnology Co Ltd (1796)?
Revenue at GeneFerm Biotechnology Co Ltd is growing +0.6% versus a year earlier (3y avg +2.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at GeneFerm Biotechnology Co Ltd (1796)?
Earnings per share at GeneFerm Biotechnology Co Ltd are growing +150% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does GeneFerm Biotechnology Co Ltd (1796) carry?
The net debt of GeneFerm Biotechnology Co Ltd is 39.8M TWD (fiscal year 2024, ≈ 0.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch GeneFerm Biotechnology Co Ltd in the live analysis
One click puts GeneFerm Biotechnology Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026